ULTRHAS - ULtrafine particles from TRansportation – Health Assessment of Sources
The EU-funded ULTRHAS project aims to disclose the health threats posed by Ultrafine Particles (UFPs) emitted from different transport modes, and provide guidance for policy development to improve air quality and health.
ULTRHAS brings together partners from the Norvegian Institute of public health (Norway), University of Eastern Finland and the Finnish Institute for Health and Welfare (Finland), University of Fribourg (Switzerland), University of Rostock and Bundeswehr University Munich (Germany) and the Comprehensive Molecular Analytics cooperation group of Hemlholtz Munich.
ULTRHAS will notably clarify the importance of physicochemical characteristics and atmospheric aging processes by applying cutting-edge exhaust generation and characterization, as well as exposure approaches. The overall objective of the project, backed by over €4 million in EU funding, is to improve risk assessment of air pollutants from transport modes and to advise policymakers and regulators on more targeted mitigation measures against the emission components and sources that contribute the most to adverse effects. This will allow for development of more efficient strategies to improve urban air quality, and promote health and wellbeing.
ULTRHAS is comprised of seven working packages. The Comprehensive Molecular Analytics group of Helmholtz Munich (Prof. Dr. Ralf Zimmermann and Dr. Sebastiano Di Bucchianico) will lead the third of these dealing with the cytotoxic, pro-inflammatory, genotoxic and mutagenic potential of different transport mode emissions in advanced and relevant mammalian lung tissue models cultured at the Air-Liquid Interface (ALI). This will determine the effects of particles physical properties versus their chemical composition, distinguish the effects of particle and gaseous phases, and unravel the toxicological effects of atmospheric aging on emission aerosols.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 955390.
ULTRHAS - ULtrafine particles from TRansportation – Health Assessment of Sources
The EU-funded ULTRHAS project aims to disclose the health threats posed by Ultrafine Particles (UFPs) emitted from different transport modes, and provide guidance for policy development to improve air quality and health.
ULTRHAS brings together partners from the Norvegian Institute of public health (Norway), University of Eastern Finland and the Finnish Institute for Health and Welfare (Finland), University of Fribourg (Switzerland), University of Rostock and Bundeswehr University Munich (Germany) and the Comprehensive Molecular Analytics cooperation group of Hemlholtz Munich.
ULTRHAS will notably clarify the importance of physicochemical characteristics and atmospheric aging processes by applying cutting-edge exhaust generation and characterization, as well as exposure approaches. The overall objective of the project, backed by over €4 million in EU funding, is to improve risk assessment of air pollutants from transport modes and to advise policymakers and regulators on more targeted mitigation measures against the emission components and sources that contribute the most to adverse effects. This will allow for development of more efficient strategies to improve urban air quality, and promote health and wellbeing.
ULTRHAS is comprised of seven working packages. The Comprehensive Molecular Analytics group of Helmholtz Munich (Prof. Dr. Ralf Zimmermann and Dr. Sebastiano Di Bucchianico) will lead the third of these dealing with the cytotoxic, pro-inflammatory, genotoxic and mutagenic potential of different transport mode emissions in advanced and relevant mammalian lung tissue models cultured at the Air-Liquid Interface (ALI). This will determine the effects of particles physical properties versus their chemical composition, distinguish the effects of particle and gaseous phases, and unravel the toxicological effects of atmospheric aging on emission aerosols.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 955390.